<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a key transcription factor regulating genes involved in adipogenesis, <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis and cell differentiation </plain></SENT>
<SENT sid="1" pm="."><plain>Moreover, PPARgamma has been demonstrated to control proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the biological effects of PPARgamma activation by the oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: PPARgamma <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein were overexpressed in endoscopic biopsies of Barrett's epithelium and the human Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell line OE33 as compared to <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus and stomach and the esophageal squamous epithelium <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell line Kyse-180 </plain></SENT>
<SENT sid="4" pm="."><plain>PPARgamma activation by <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in OE33 cells in vitro led to reduced cell growth by induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Effects of systemic PPARgamma activation by the thiazolidinedione <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were then assessed in vivo in <z:mp ids='MP_0003815'>nude</z:mp> mice bearing transplantable Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> derived from OE33 cells </plain></SENT>
<SENT sid="6" pm="."><plain>Unexpectedly, enhanced growth of OE33 derived transplantable <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> was observed in Balb/c nu/nu mice upon systemic <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment due to <z:mp ids='MP_0000351'>increased cell proliferation</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: These results indicate that PPARgamma is involved in the molecular pathogenesis of Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> formation and growth </plain></SENT>
<SENT sid="8" pm="."><plain>However, activation of PPARgamma exerts differential effects on growth of Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells in vitro and in vivo emphasizing the importance of additional cell context specific factors and systemic metabolic status for the modulation of PPARgamma action in vivo </plain></SENT>
</text></document>